Gilead Sciences shares declined by 1.38% in the latest trading session, underperforming the broader market despite sector gains. Trading volume rose by 12% compared to the 30-day average, indicating elevated investor activity. The stock’s 50-day moving average stands modestly above its 200-day average, reflecting recent consolidation around its longer-term trend line.

Abacus FCF Advisors LLC reduced its position in Gilead Sciences by 16.0% in the third quarter, selling 26,340 shares and ending the period with 138,674 shares valued at approximately $15.4 million. The holding represented 2.0% of the firm’s assets, making it its 24th largest position. Meanwhile, Norges Bank initiated a new stake worth roughly $2.15 billion in the second quarter. Ameriprise Financial boosted its position by 397.6%, acquiring an additional 5.4 million shares, and Invesco lifted its stake by 33.5%, adding 3.4 million shares. Assenagon Asset Management grew its position by 164.4% with a purchase of 2.17 million shares. Overall, institutional ownership accounts for over 83% of outstanding shares.

Insider selling accelerated over the past quarter, with Chief Legal Officer Johanna Mercier offloading 3,000 shares for proceeds of $366,000 and Director Jeffrey Bluestone selling 5,000 shares for $625,400. Total insider dispositions reached 126,257 shares valued at $15.6 million, representing a 2.75% reduction in Mercier’s stake and a 35.92% cut in Bluestone’s holding. Insider ownership now stands at just 0.27% of the company’s outstanding stock.

In its most recent quarter, Gilead reported adjusted EPS of $2.47, surpassing consensus estimates by $0.31, on revenue of $7.77 billion versus expectations of $7.42 billion. Net margin expanded to 27.9%, while return on equity reached 51.9%. Year-over-year revenue growth was 3.0%. The company issued guidance for full-year EPS of 8.05 to 8.25, above the current analyst consensus of 7.95. A quarterly dividend of $0.79 was declared, corresponding to a 2.5% yield and a payout ratio of 49%.